Active, not recruitingPHASE1, PHASE2NCT04355689
Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome
Studying Usher syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Nacuity Pharmaceuticals, Inc.
- Principal Investigator
- Lee Anderson, MDNacuity Pharmaceuticals, Inc.
- Intervention
- NPI-001(drug)
- Enrollment
- 49 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2026
Study locations (4)
- Queensland Eye Institute, Brisbane, Australia
- CERA, Melbourne, Australia
- Lions Eye Institute, Perth, Australia
- Sydney Eye Hospital / Save Sight Institute, Sydney, Australia
Collaborators
Foundation Fighting Blindness
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04355689 on ClinicalTrials.govOther trials for Usher syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07278843Natural History of Photoreceptor Degeneration in USH1B: Clinical Parameters and Validation of Functional Vision Tests in MYO7ACentre Hospitalier National d'Ophtalmologie des Quinze-Vingts
- RECRUITINGNCT04665726Natural History Study of Usher Syndrome ( Light4Deaf )Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts